Pfizer Nears $7.3 Billion Acquisition of Metsera, Reports Financial Times

Pfizer is reportedly close to a $7.3 billion deal to acquire Metsera, a US weight-loss drug developer. The acquisition would give Pfizer a foothold in the anti-obesity treatment market after its experimental weight-loss drug, danuglipron, failed in trials earlier this year. Neither company has commented on the potential deal, which could be announced as soon as Monday.

Pfizer is reportedly close to finalizing a deal to acquire weight loss drug developer Metsera for up to $7.3 billion. According to sources, Pfizer plans to pay $47.50 per share in cash, with an additional $22.50 per share if Metsera achieves certain performance targets Pfizer Nearing $7.3 Billion Acquisition of Weight Loss Drug Developer Metsera^[1]. This acquisition could be officially announced as early as Monday, barring any last-minute delays.

The acquisition comes after Pfizer scrapped its own obesity drug candidate, danuglipron, earlier this year. Metsera, which is listed in one of 2025’s biggest biotech IPOs, has drawn significant interest with its GLP-1 therapy, MET-097i, which produced 11.3% weight loss over 12 weeks in a mid-stage trial Pfizer Stock Draws Focus On Report Of $7.3B Deal Plan For Metsera Buyout As Obesity Drug Race With Lilly, Novo Heats Up^[2]. Metsera is also developing a monthly shot and an oral pill, positioning it as a strong competitor in the anti-obesity treatment market.

The deal would put Pfizer in direct competition with Eli Lilly and Novo Nordisk, whose blockbuster GLP-1 drugs Zepbound and Wegovy are expanding into pill form. Pfizer’s stock has declined 4.6% so far in 2025, while Metsera’s stock has risen 25.7% over the same period Pfizer Stock Draws Focus On Report Of $7.3B Deal Plan For Metsera Buyout As Obesity Drug Race With Lilly, Novo Heats Up^[2].

The acquisition is seen as a strategic move by Pfizer CEO Albert Bourla, who has been under pressure to reignite growth. The last major deal by Pfizer was the $43 billion purchase of cancer drugmaker Seagen in 2023. Retail sentiment for both Pfizer and Metsera on Stocktwits was ‘bullish’, with message volume ‘normal’ for Pfizer and ‘high’ for Metsera Pfizer Stock Draws Focus On Report Of $7.3B Deal Plan For Metsera Buyout As Obesity Drug Race With Lilly, Novo Heats Up^[2].